Not recruitingISRCTN16838597

A phase three randomised, placebo-controlled, clinical trial to study the safety and efficacy of three doses of lurasidone hydrochloride (HCl) in acutely psychotic patients with schizophrenia

Research studyAges 18+Multiple countries

The study in practice

Understand this study

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNot clearly listed

Recruitment status: Not recruiting
Enrollment listed in the registry: Not clearly listed
Sponsor: Dainippon Sumitomo Pharma America Inc. (USA)
Sponsor type: Pharmaceutical company
Study type: Other
Intervention type: Other / unclear
Study phase: Not clearly listed
Locations: United States, France, United Kingdom, ...
Age range: Over 18 Years
Official registry ID: ISRCTN16838597
Official title: Show the full official title
A phase three randomised, placebo-controlled, clinical trial to study the safety and efficacy of three doses of lurasidone hydrochloride (HCl) in acutely psychotic patients with schizophrenia

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

Not recruiting

United Kingdom · France · India

5 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Dainippon Sumitomo Pharma America Inc. (USA), a pharmaceutical company.

Who can participate?

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as not recruiting.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.